Cargando…

Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine

To re-analyse the clinical outcomes and interferon (IFN) activity data from the JOQUER trial, a phase III trial investigating hydroxychloroquine (HCQ) in patients with primary Sjögren’s syndrome (pSS), after stratifying patients into putative pathobiological subgroups utilizing the Newcastle Sjögren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collins, Alexis, Lendrem, Dennis, Wason, James, Tarn, Jessica, Howard-Tripp, Nadia, Bodewes, Iris, Versnel, Marjan A., Gottenberg, Jacques-Eric, Seror, Raphaele, Mariette, Xavier, Ng, Wan-Fai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316226/ https://www.ncbi.nlm.nih.gov/pubmed/34165604 http://dx.doi.org/10.1007/s00296-021-04927-y

Ejemplares similares

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial
por: Bodewes, Iris L A, et al.
Publicado: (2020)

Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
por: Hassold, Nolan, et al.
Publicado: (2022)

Comorbidities in the UK Primary Sjögren’s Syndrome Registry
por: Tarn, Jessica, et al.
Publicado: (2022)

Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study
por: Davies, Kristen, et al.
Publicado: (2019)

Primary Sjögren's syndrome: Longitudinal real‐world, observational data on health‐related quality of life
por: Tarn, Jessica, et al.
Publicado: (2022)

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
por: Payet, J, et al.
Publicado: (2015)

Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials
por: Tarn, Jessica R, et al.
Publicado: (2019)

Impact of patient ancestry on heterogeneity of Sjögren’s disease
por: Beydon, Maxime, et al.
Publicado: (2023)

Exploring the biological basis of fatigue using primary Sjögren's syndrome as a disease model
por: Natasari, Andini Savietri, et al.
Publicado: (2013)

Seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome
por: Duret, Pierre-Marie, et al.
Publicado: (2020)

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
por: Seror, Raphaèle, et al.
Publicado: (2015)

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019)

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)

Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary Sjögren’s Syndrome
por: Flessa, Christina-Maria, et al.
Publicado: (2022)

Making Sense of Intracellular Nucleic Acid Sensing in Type I Interferon Activation in Sjögren’s Syndrome
por: Huijser, Erika, et al.
Publicado: (2021)

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
por: Traianos, Emmanuella Young, et al.
Publicado: (2020)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Comparison between primary Sjögren’s disease patients with high or low level of dryness
por: Kachaner, Alexandra, et al.
Publicado: (2023)

The clinical relevance of animal models in Sjögren’s syndrome: the interferon signature from mouse to man
por: Maria, Naomi I, et al.
Publicado: (2015)

CTLA-4 polymorphism and primary Sjögren's syndrome: authors' response
por: Miceli-Richard, Corinne, et al.
Publicado: (2007)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Fatigue in Sjögren's Syndrome: A Search for Biomarkers and Treatment Targets
por: Bodewes, Iris L. A., et al.
Publicado: (2019)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjögren's syndrome
por: Collins, K S, et al.
Publicado: (2013)

Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions
por: Miyamoto, Samira Tatiyama, et al.
Publicado: (2019)

Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
por: Yang, Deng-Ho, et al.
Publicado: (2020)

Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study
por: Seror, Raphaèle, et al.
Publicado: (2015)

Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus
por: Trutschel, Diana, et al.
Publicado: (2022)

Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype
por: Huijser, Erika, et al.
Publicado: (2022)

Cutaneous purpura of Sjögren syndrome successfully treated with hydroxychloroquine
por: Hile, Grace A., et al.
Publicado: (2017)

Revisiting the cardiovascular risk of hydroxychloroquine in RA
por: Pers, Yves-Marie, et al.
Publicado: (2020)

Efficacy of an Intranasal Tear Neurostimulator in Sjögren Syndrome Patients
por: Lilley, Jonathan, et al.
Publicado: (2021)

Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren’s syndrome
por: Huijser, Erika, et al.
Publicado: (2022)

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response
por: Hamkour, Safae, et al.
Publicado: (2023)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups
por: Yao, Katharine, et al.
Publicado: (2015)

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?
por: Devauchelle-Pensec, Valérie, et al.
Publicado: (2015)

Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines
por: Howard Tripp, Nadia, et al.
Publicado: (2016)

Fish Consumption and Risk of Rheumatoid Arthritis: Findings from the E3N Cohort Study
por: Nguyen, Yann, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ffkjse75qlrlc1dr7tds1d5e07